This study assessed the safety and preliminary efficacy of these medications in subjects with rheumatoid arthritis. The primary endpoint was the proportion of subjects meeting the ACR20 criteria .
Further studies are in progress.
Complement inhibition returned to baseline at 14 days at the two highest doses. There was no significant antibody responses to the infused antibody. Activated T cells ultimately produce an inflammatory immune response resulting in joint destruction. Mild adverse events unrelated to treatment were reported. All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only.